Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Enrollment patterns and site-level predictors of Black participant recruitment to a multisite randomized clinical trial (RCT) of endocrine therapy adherence support.
Ivory, Joannie M. , Gunn, Heather, Naughton, Michelle J. , McCue, Shaylene , Wills, Rachel, Williams, Kayla , Reeder‐Hayes, Katherine E. , Wheeler, Stephanie B. , Drier, Sarah , Paskett, Electra D. , Williams, Kayla

Mayo Clinic

Journal of Clinical Oncology | September 30, 2022 | Volume: 40 | Issue: 28_suppl | Pages: 68-68

10.1200/jco.2022.40.28_suppl.068 Get It

68 Background: Accrual of racial and ethnic minority patients (pts) to clinical trials has been an ongoing challenge in research. Barriers exist at many levels of engagement including trial availability, screening biases, strict enrollment criteria, and structural racism. Lack of trial diversity has led to less generalizable medical evidence, suboptimal data for toxicity and efficacy of cancer treatments, poorer outcomes and continued mistrust by communities of color in research processes that exclude or marginalize them. Site factors and study design strategies associated with successful recruitment of diverse study populations are understudied. Methods: Alliance A191901 is an RCT testing combinations of text and telephone support to promote endocrine therapy adherence among breast cancer survivors. It oversamples Black participants and those < 50 years at thresholds of 30% each. Administrative enrollment data was used to track and describe monthly accrual trajectory by race among the initial 50% of participants (n = 590) and to examine associations between % Black participants accrued and accruing site characteristics, including site type, geographic region, % Black population in the site’s zip code and volume of pts by race accrued to recent (2018-2019) Alliance trials, using χ2 tests. We also examined patterns of Black participant accrual before and after closure of the A191901 study to non-Black participants. Results: At 50% accrual, 124 sites had enrolled at least 1 participant. Among 590 participants, 9.7% were Black and 22.5% were < 50 years. Neither site type nor volume was associated with % Black participants recruited. Sites in the South recruited higher proportions of Blacks (19.0% vs 5.6% for Midwest, the lowest region, p < 0.001). Neighborhood racial composition was positively associated with accrual of Black participants (17.2% at sites from highest Black composition vs. 2.3% in lowest, p < 0.001). Recruitment trajectories of Black participants consistently lagged those of non-Black participants in the first half of the study; however, Black participants recruited per month numerically increased after the study reached target accrual of non-Blacks and closed to non-Black participants. Conclusions: Sites in neighborhoods and geographic regions with larger Black populations recruited higher proportions of Black participants, but site type and volume were not associated with recruitment of Black participants. Closure of non-Black study strata based on predetermined accrual targets may positively impact recruitment trajectories of Black participants, but further study is needed. Site selection based on neighborhood composition and geography may be an appropriate tool for increasing trial diversity. Support: UG1CA189823. Clinical trial information: NCT04379570.
Determinants of low-value imaging for patients with low-to-intermediate risk microscopic hematuria.
Peluso, Alexandra, Bundy, Richa , Witek, Lauren , Krol, Bridget , Pathak, Ram A. , Birken, Sarah A. , Wagi, Cheyenne R. , Nielsen, Matthew E. , Matulewicz, Richard S. , Parchman, Michael Leo , Dharod, Ajay

Mayo Clinic

Journal of Clinical Oncology | September 30, 2022 | Volume: 40 | Issue: 28_suppl | Pages: 27-27

10.1200/jco.2022.40.28_suppl.027 Get It

27 Background: In the US, two million people are referred to urologists for the evaluation of microscopic hematuria (MH). MH guidelines were revised in 2020 by the American Urological Association, recommending that only patients at high risk for malignancy based on age, smoking history, or urinalysis receive computed tomography (CT) imaging. We found in previous studies that providers continued to use CT for patients with low-to-intermediate risk, representing low-value care. To understand reasons for continued CT use for patients with low-to-intermediate risk MH, we assessed determinants of low-value care in a concurrent mixed-method study. Methods: We stratified patients with a urology consultation within 180 days of a urinalysis documented in one academic medical center’s electronic health record between 1/1/15 and 7/1/21 into high-, intermediate-, and low-risk categories and validated risk designation in a chart review of a 5% subsample. We defined low-value care as CT for patients with low-to-intermediate-risk MH. To assess determinants of low-value MH care, we conducted semi-structured interviews with primary, urology, and gynecology providers (n = 7) identified through our professional networks. Results: Six hundred nineteen patients were referred to urology for MH. 58.6% were high-risk, 33.6% intermediate-risk, 4.4% low-risk, and 3.4% were undefined. 15.9% of intermediate-risk (n = 33) and 11.1% of low-risk (n = 3) patients received CT. Of the 14 patients referred to urology post-guideline change, none with low-to-intermediate-risk received CT. Interviews demonstrated substantial variation in approaches to MH evaluation. Urologists were largely aware of the revised guideline but noted inappropriate evaluation before referral, unnecessary referrals, and inefficiency in evaluation following referral. Lacking accessible data for risk stratification, other providers’ approaches were varied but driven by a common goal of ruling out renal malignancy, based on medical school training and institutional norms. Conclusions: Low-value care was limited but persistent and may be driven by a lack of resources to support risk-stratified MH evaluation, including accessible risk stratification data and clear guidelines for appropriate evaluation. This is consistent with a lack of practical guidance for implementing MH evaluation guidelines. In future studies, we will develop strategies to facilitate risk-stratified MH evaluation in practice.
Understanding Modern Medical Centers: Beyond Simone—Intersectional Maxims for a New Era
Graff, Stephanie L. , Wildes, Tanya M. , Duma, Narjust , Dizon, Don S. , LoConte, Noelle K. , Mitchell, Edith, Murphy, Martina, Perez, Edith A. , Temkin, Sarah M. , Kunz, Pamela L. , Winkfield, Karen M. , Florez, Narjust , Wildes, Tanya , LoConte, Noelle , Graff, Stephanie L , Temkin, Sarah M

Mayo Clinic

Journal of Clinical Oncology | September 27, 2022 | Volume: 41 | Issue: 7 | Pages: 1350-1358

10.1200/jco.22.01060 | PMID 36166718 Get It

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes
Dietrich, Mary S. , Gaitatzis, Katrina , Koelmeyer, Louise , Boyages, John , Abramson, Vandana G. , McLaughlin, Sarah A. , Ngui, Nicholas , French, James , Hsu, Jeremy , Hughes, Michael , Stolldorf, Deonni P. , Shah, Chirag , Ridner, Sheila H. , Ridner, Sheila H , Abramson, Vandana G , Koelmeyer, Louise A , Elder, Elisabeth Edström

Mayo Clinic

Lymphatic Research and Biology | September 20, 2022 | Volume: 21 | Issue: 3 | Pages: 304-313

10.1089/lrb.2022.0020 | PMID 36126315 Get It

Background: Patients underwent a compression (sleeve and gauntlet) intervention for subclinical breast cancer-related lymphedema (S-BCRL). Physical, emotional, and quality-of-life (QoL) outcomes were examined. Associations of change in extracellular fluid alone through bioimpedance spectroscopy (BIS) or change in whole-arm volume through tape measure with the outcomes at time of S-BCRL were explored. Methods and Results: We enrolled newly diagnosed nonmetastatic breast cancer patients for surveillance up to 36 months postoperatively. Upon detection of S-BCRL, a 28-day compression intervention was initiated. Data were obtained through physical examination/measurement and self-report instruments: skin examination, Lymphedema Symptom Intensity and Distress Survey-Arm, and Functional Assessment of Cancer Therapy General (FACT-G), Breast (FACT-B), and FACT-B+4. Improvements with intervention were observed in the proportion of patients reporting symptom scores ≥3 in function (Cohen's d = −0.46, p < 0.01), in biobehavioral (Cohen's d = −0.30, p < 0.05), maximum number of skin conditions (Cohen's d = −0.34, p < 0.05. 3), FACT-B (Cohen's d = 0.52, p < 0.01), and FACT-B + four (Cohen's d = −0.42, p < 0.01). At the study endpoint, compared with those who did not progress, chronic breast cancer-related lymphedema (C-BCRL) progressing patients had higher overall symptom scores ( p = 0.037), more skin conditions ( p = 0.009), and lower total FACT-G and FACT-B scores ( p < 0.05). At the time of S-BCRL, detection of greater BIS unit change correlated with higher symptom, skin condition, and QoL values. Greater whole-arm volume change correlated with higher FACT-B+4 scores (all p < 0.05). Conclusions: Prospective surveillance, symptom assessment, and compression intervention promote low progression rates from S-BCRL to C-BCRL and as such reduce symptom burden. This closed study is registered with ClinicalTrials.gov NCT02167659
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma
Furqan, Fateeha , Ahn, Kwang Woo , Abutalib, Syed A., Ahmed, Sairah , Kharfan‐Dabaja, Mohamed A. , Friedberg, Johnathan, Gregory, Tara, Hill, LaQuisa C. , Sterling, Cole , Barta, Stephan K., Herrera, Alex F. , Sauter, Craig S. , Ahmed, Sairah , Perales, Miguel-Angel , Hamadani, Mehdi , Hill, LaQuisa C , Chen, Yue , Kaur, Manmeet, Ahmed, Nausheen , Shadman, Mazyar , Perales, Miguel‐Angel , Zain, Jasmine , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | September 19, 2022 | Volume: 200 | Issue: 1 | Pages: 54-63

10.1111/bjh.18467 | PMID 36120837 Get It

Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated outcomes of 182 adults (aged ≥18 years) with R/R ALCL undergoing allo‐HCT between 2008 and 2019. Non‐relapse mortality (NRM), disease relapse/progression (REL), progression‐free survival (PFS), and overall survival (OS) were modelled using Cox proportional hazards models. The median (range) follow‐up of survivors was 62 (3–148) months. The 1‐year NRM was 18%. The 5‐year REL, PFS and OS were 32%, 41% and 56% respectively. On multivariable regression analysis African American race (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.6–4.8; p < 0.001) and refractory disease at allo‐HCT (HR 3.2, 95% CI 1.6–6.2; p < 0.001) were predictive of inferior OS. Similarly, African‐American race (HR 2.1, 95% CI 1.3–3.4; p = 0.003), other minority race (HR 2.5, 95% CI 1.2–5.3; p = 0.02) and refractory disease (HR 2.2, 95% CI 1.2–4.3; p = 0.01) were predictive of inferior PFS. These data, demonstrate that allo‐HCT can result in durable disease control in a sizable proportion of patients with R/R ALCL. Refractory disease and racial minority status predicted inferior allo‐HCT outcomes. Whether the inferior outcomes of racial minorities with R/R ALCL after allo‐HCT are driven by differences in disease biology or disparities in post allo‐HCT care, or both, requires further investigation.
Tumor Microenvironment CD14+ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma
Withers, Sarah G., Bulur, Peggy A. , Dietz, Allan B. , Boland, Jennifer M. , Dietz, Allan B , Schenk, Erin L.

Mayo Clinic

Cancers | September 18, 2022 | Volume: 14 | Issue: 18 | Pages: 4501

10.3390/cancers14184501 | PMID 36139660 Get It

Patients with early-stage lung adenocarcinoma have a high risk of recurrent or metastatic disease despite undergoing curative intent therapy. We hypothesized that increased CD14+ cells within the tumor microenvironment (TME) could stratify patient outcomes. Immunohistochemistry for CD14 was performed on 189 specimens from patients with lung adenocarcinoma who underwent curative intent surgery. Outcomes and associations with clinical and pathologic variables were determined. In vitro studies utilized a coculture system to model the lung cancer TME containing CD14+ cells. Patients with high levels of TME CD14+ cells experienced a median overall survival of 5.5 years compared with 8.3 and 10.7 years for those with moderate or low CD14 levels, respectively (p < 0.001). Increased CD14+ cell tumor infiltration was associated with a higher stage at diagnosis and more positive lymph nodes at the time of surgery. This prognostic capacity remained even for patients with early-stage disease. Using an in vitro model system, we found that CD14+ cells reduced chemotherapy-induced cancer cell death. These data suggest that CD14+ cells are a biomarker for poor prognosis in early-stage lung adenocarcinoma and may promote tumor survival. CD14+ cell integration into the lung cancer TME can occur early in the disease and may be a promising new therapeutic avenue.
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
Esplin, Edward D. , Nielsen, Sarah M. , Bristow, Sara L. , Garber, Judy E. , Hampel, Heather , Rana, Huma Q. , Samadder, N. Jewel , Shore, Neal D. , Nussbaum, Robert L. , Nussbaum, Robert , Garber, J. E. , Hampel, Heather , Esplin, Edward D , Rana, Huma Q , Shore, Neal

Mayo Clinic

JCO Precision Oncology | September 15, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.21.00516 | PMID 36108258 Get It

Brachial artery trauma as a complication of bicep muscle injury
Graham, Charles H. , Bergkvist, Sarah, Kimball, Peter, Taylor, Katelyn, Syed, Mudassir , Mohseni, Michael , Graham, Charles, Mohseni, Michael M , Graham, Charles, Kimball, Peter

Mayo Clinic

Baylor University Medical Center Proceedings | September 15, 2022 | Volume: 36 | Issue: 1 | Pages: 126-127

10.1080/08998280.2022.2123662 | PMID 36578592 Get It